

13. (Amended) The protein of claim 67, wherein the target is a biological entity.
14. (Amended) The protein of claim 67, wherein the target is an organ, tumor, tissue, cell, virus, or microorganism.
15. (Amended) The protein of claim 67, wherein the target is a synthetic or naturally occurring macromolecule.
16. (Amended) The protein of claim 67, wherein the target is a protein.
17. (Amended) The protein of claim 67, wherein the target is a cell surface protein.
18. (Amended) The protein of claim 67, wherein the target is an integrin.
19. (Amended) The protein of claim 67, wherein the target is an integrin that binds to an Arg-Gly-Asp tripeptide motif.
20. (Amended) The protein of claim 67, wherein the target is $\alpha\text{IIb}\beta_3$ integrin.
21. (Amended) The protein of claim 67, wherein the target is $\alpha_v\beta_3$ integrin.

22. (Amended) The protein of claim 67, wherein the optimized, protein surface loop is a complementarity determining region of an IgG-like molecule.

23. (Amended) The protein of claim 67, wherein the optimized, surface loop is a complementarity determining region of an antibody molecule.

24. (Amended) The protein of claim 23, wherein the complementarity determining region is heavy chain complementarity determining region 3 of monoclonal antibody Fab-9.

65. (Amended) The protein of claim 67, wherein the protein is loop-grafted tissue type plasminogen activator.

Please add the following new claim.

67. (New) A protein linked to an exogenous protein surface loop, wherein the exogenous protein surface loop consists of an optimized protein surface loop that specifically binds a selected target, and replaces an endogenous protein surface loop on the protein, and wherein the protein is selected from the group consisting of an enzyme, a thrombolytic agent, an anticoagulant, an apoptotic protein, a growth factor, a cytokine and a cell surface receptor ligand.